A Phase 4 interventional study of Rosuvastatin in Type 2 Diabetes, sponsored by AstraZeneca. Completed at 84 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-31.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 54th largest by enrollment of the 280 interventional ones that give a count, is one of 33 that started in 2008, is one of 28 in phase 4, and was the 97th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
345 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 47 · Phase 3 122 · Phase 4 28
First in 2001; this study’s year is marked. 33 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 598 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 155 across the 280 interventional studies, 2,000 across the 65 observational. Of the 325 that completed or were terminated, 149 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
5 of the studies in Diabetes Mellitus, Type 2 by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723833AstraZenecaA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | 2026-11-18 |
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step after 6 weeks of therapy in type 2 diabetic patients previously treated with another statin and not at LDL-C targets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
titrated
Drug: Rosuvastatin
Non-titrated
Drug: Rosuvastatin
Oral
Also known as: Crestor
Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy
The number of subjects achieving Canadian Low density lipoprotein cholesterol (LDL-C) target goals (i.e. LDL-C ≤ 2.0 mmol/L) over the total number subjects treated after 12 weeks of rosuvastatin therapy multiplied by 100
Time frame: 12 Weeks
Percentage of Subjects Achieving Total Cholesterol (TC)/ High-density Lipoprotein Cholesterol (HDLC) Ratio (i.e. TC/HDL < 4.0 mmol/L) at 6 and 12 Weeks of Treatment
Proportion of subjects achieving total cholesterol (TC)/ High-density lipoprotein cholesterol (HDLC) ratio (i.e. TC/HDL \< 4.0 mmol/L) at 6 and 12 weeks of treatment
Time frame: 6 and 12 Weeks
Mean Percent Change in Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDLC) , TC/HDL-C Ratio, Non-HDL-C, Triglycerides and Apolipoprotein B (ApoB) /Apolipoprotein A1 (ApoA-1) Ratio
Time frame: 6 and 12 Weeks
Mean High Sensitivity C-reactive Protein (hsCRP) Value at Week 6 and 12
Time frame: 6 and 12 Weeks
Incidence of Adverse Events and Abnormal Laboratory Values After 12 Weeks of Therapy
Time frame: 6 and 12 Weeks
A total of 1044 patients (adult male and non-pregnant females) were enrolled at 122 Canadian family practice sites between May 2008 and May 2009. Out of these, only 598 patients were allocated to treatment. The remaining 446 did not receive treatment as they did not fulfill the inclusion/exclusion criteria.
| Milestone | Rosuvastatin Titrated | Rosuvastatin Non-titrated |
|---|---|---|
| Started | 154 | 444 |
| Completed | 153 | 401 |
| Not completed | 1 | 43 |
| Withdrew: Adverse event | 0 | 15 |
| Withdrew: Lost to follow-up | 0 | 10 |
| Withdrew: Withdrawal by subject | 0 | 6 |
| Withdrew: Did not receive treatment | 0 | 1 |
| Withdrew: Incorrect enrollment | 0 | 6 |
| Withdrew: Severe non-compliance to protocol | 0 | 1 |
| Withdrew: Not reported | 1 | 4 |
The number of subjects achieving Canadian Low density lipoprotein cholesterol (LDL-C) target goals (i.e. LDL-C ≤ 2.0 mmol/L) over the total number subjects treated after 12 weeks of rosuvastatin therapy multiplied by 100
| Percentage | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Rosuvastatin 20 mg (Titrated) | Rosuvastatin 40 mg (Titrated) |
|---|---|---|---|---|
| Percentage of Subjects Achieving Canadian Low Density Lipoprotein Cholesterol (LDL-C) Target Goals (i.e. LDL-C ≤ 2.0 mmol/L) After 12 Weeks of Rosuvastatin Therapy | 87 ± 82 | 87 ± 81 | 76 ± 65 | 63 ± 52 |
Proportion of subjects achieving total cholesterol (TC)/ High-density lipoprotein cholesterol (HDLC) ratio (i.e. TC/HDL \< 4.0 mmol/L) at 6 and 12 weeks of treatment
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10 mg (Initial) | — | 4/319 (1.3%) | 14/319 (4.4%) |
| Rosuvastatin 10 mg (Continued, Non-titrated) | — | 2/232 (0.9%) | 4/232 (1.7%) |
| Rosuvastatin 20 mg (Initial) | — | 0/279 (0%) | 9/279 (3.2%) |
| Rosuvastatin 20 mg (Continued, Non-titrated) | — | 0/182 (0%) | 3/182 (1.6%) |
| Rosuvastatin 20 mg (Titrated) | — | 1/75 (1.3%) | 2/75 (2.7%) |
| Rosuvastatin 40 mg (Titrated) | — | 1/78 (1.3%) | 0/78 (0%) |
| Event | Rosuvastatin 10 mg (Initial) | Rosuvastatin 10 mg (Continued, Non-titrated) | Rosuvastatin 20 mg (Initial) | Rosuvastatin 20 mg (Continued, Non-titrated) | Rosuvastatin 20 mg (Titrated) | Rosuvastatin 40 mg (Titrated) |
|---|---|---|---|---|---|---|
| CellulitisSkin and subcutaneous tissue disorders | 0/319 | 0/232 | 0/279 | 0/182 | 1/75 | 0/78 |
| Aortic Aneurysm RuptureCardiac disorders | 0/319 | 0/232 | 0/279 | 0/182 | 0/75 | 1/78 |
| LabyrinthitisEar and labyrinth disorders | 0/319 | 1/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Chemical PoisoningInjury, poisoning and procedural complications | 0/319 | 1/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Renal ColicRenal and urinary disorders | 1/319 | 0/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Urinary Tract InfectionRenal and urinary disorders | 1/319 | 0/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Cerebrovascular AccidentNervous system disorders | 1/319 | 0/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Urinary RetentionRenal and urinary disorders | 1/319 | 0/232 | 0/279 | 0/182 | 0/75 | 0/78 |
| Event | Rosuvastatin 10 mg (Initial) | Rosuvastatin 10 mg (Continued, Non-titrated) | Rosuvastatin 20 mg (Initial) | Rosuvastatin 20 mg (Continued, Non-titrated) | Rosuvastatin 20 mg (Titrated) | Rosuvastatin 40 mg (Titrated) |
|---|---|---|---|---|---|---|
| BronchitisRespiratory, thoracic and mediastinal disorders | 2/319 | 3/232 | 1/279 | 0/182 | 2/75 | 0/78 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/319 | 1/232 | 2/279 | 1/182 | 0/75 | 0/78 |
| ConstipationGastrointestinal disorders | 5/319 | 0/232 | 6/279 | 2/182 | 0/75 | 0/78 |
| Age Continuous(Years) | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Total |
|---|---|---|---|
| Mean | 63.2 ± 10.9 | 62.6 ± 10.5 | 62.9 ± 10.7 |
| Sex: Female, Male(Participants) | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Total |
|---|---|---|---|
| Female | 150 | 145 | 295 |
| Male | 169 | 134 | 303 |
| Race/Ethnicity, Customized(Participants) | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Total |
|---|---|---|---|
| White | 288 | 245 | 533 |
| Black/African American | 5 | 7 | 12 |
| Asian | 22 | 17 | 39 |
| Other | 4 | 10 | 14 |
| Body Mass Index(kg/m^2) | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Total |
|---|---|---|---|
| BMI | 32.50 ± 6.89 | 32.27 ± 6.72 | 32.39 ± 6.81 |
| Waistline circumference(cm) | Rosuvastatin 10 mg (Initial) | Rosuvastatin 20 mg (Initial) | Total |
|---|---|---|---|
| Mean | 106.7 ± 14.9 | 106.7 ± 15.9 | 106.7 ± 15.4 |
The record gives a start of May 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosuvastatin